Telehealth platforms restructure around brand-only models
Membership billed separately from medication became the dominant structure at the large consumer platforms.
Membership billed separately from medication became the dominant structure at the large consumer platforms.
All-in monthly cost at 2.4 mg
Through late 2025 the large consumer telehealth names converged on a similar structure: a membership or programme fee for clinical services, with brand-name medication billed separately and frequently through insurance.
That is a different product from the all-in compounded subscription that preceded it, and the advertised figure means something different. A $99 membership is not a $99 medication cost.
Every price on this site is stated all-in for that reason, and programmes using split pricing are tagged as such so the two are never compared as though they were alike.
For a patient with coverage, split pricing is frequently cheaper. For a cash payer it is frequently much more expensive, and the difference is invisible in a headline.
How to read a market story in this market
Market stories change who is selling rather than what the medicine does, and they land on patients at renewal rather than in advance.
The practical exposure is to programmes you cannot easily replace. A long prepaid term with a programme whose pharmacy you cannot identify is the worst combination, because both the money and the supply chain are opaque at the moment you need them not to be.
What this does not change
The prescription requirement, the licensing framework behind a dispensing pharmacy, and the clinical review that should sit in front of any prescription. Those are stable and none of the developments we track has altered them.
It also does not change the arithmetic of choosing a programme: price the dose you expect to hold, add every recurring fee, and verify the pharmacy. The cheapest verified route we track is NexLife at $145 a month all-in at a maintenance dose, about $1,740 for a first year.
Where a development does move those figures, the tables regenerate from the dataset on the next build rather than being edited by hand.
When urgency is the product
Regulatory and market news is routinely used as a sales device. A programme citing a rule change to push you into a twelve-month prepayment is using a real fact to manufacture a deadline that does not apply to you.
The test is simple: does the development change what you can lawfully be prescribed this month? Almost never. Does it change what you should pay? Sometimes. Does it require you to decide today? Essentially never — and a programme insisting otherwise has told you how it treats patients under commercial pressure.
Where market sits in the sequence
Order matters more than most guidance admits. Establish coverage first, because a covered prescription under a documented indication beats every cash route here. Then establish the dose you expect to hold. Only then compare prices.
Most people do this backwards — compare prices, enrol, then discover an indication they already qualified for. Semaglutide has more of those routes than most weight-management drugs: type 2 diabetes, cardiovascular risk reduction, and a liver indication for a narrow population.
The check that costs nothing
Ask which pharmacy fills the prescription and search your state board's licensee register for it. Two minutes, free, and possible for only 6 of the 20 priced programmes because the rest do not name one.
A name and a licence number is the good answer. A category is incomplete but honest. A deflection about proprietary partnerships is the answer.
Why this matters more here than for approved medicines
An approved product has been reviewed before marketing and is made under a federal quality system with supply-chain traceability. A compounded preparation has not been through that review. Its assurance comes from the pharmacy, the state board licensing it, and at good operations batch testing for sterility and potency.
That is a legitimate framework rather than a loophole, and it moves verification work onto you. It is the honest reason the compounded price is lower.
Reading this alongside the rest of the site
Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.
If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.
What we would need to change our mind
A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.
All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.
What this site will not do
Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.
Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.
Who this site is not for
Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.
If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $145 a month all-in at a 2.4 mg maintenance dose, about $1,740 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.